NEWS
FDA Approves New Drugs to Treat Skin, Blood, and Lung Cancers
In the last 2 weeks of August, the Food and Drug Administration (FDA) approved three new cancer drugs: vemurafenib (Zelboraf), for patients with unresectable or metastatic melanoma whose tumors harbor a specific genetic mutation in the BRAF gene; brentuximab vedotin (Adcetris), for some patients with Hodgkin lymphoma and anaplastic large cell lymphoma; and crizotinib (Xalkori), for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have a gene fusion caused by a chromosomal translocation involving the ALK gene. Read more > >
Negative Colonoscopy Associated with Low Colorectal Cancer Risk
Low risk for developing cancer extends two decades and longerSmokers at Greater Risk of Bladder Cancer than Previously Estimated
The proportion of bladder cancer attributable to smoking is now similar in women and menHereditary Mutations in BAP1 Gene Raise Risk of Mesothelioma
BAP1 mutations may play a role in melanomas of the eye and benign skin tumorsUse of Radioactive Iodine to Treat Thyroid Cancer on the Rise
Use varies widely for high-risk and low-risk diseaseColorectal Cancer Genomes Sequenced
Study suggests that fused genes may play a role in the disease
COMMENTARY
Inside NCI: A Conversation with Dr. Norm Coleman about Radiation Research 
The associate director of NCI's Radiation Research Program discusses his research and specialized initiatives of the program.
IN DEPTH
Clinical Trial Shows Potential Benefit of HPV Vaccine for Anal Cancer
Vaccine provides protection against anal HPV infection
Targeting the Accomplices: Homing in on Immune Cells that Aid Tumors
Tumor-associated macrophages appear to help tumors grow and spread
The Art of Medicine: Using Narrative and the Humanities in Medical Training
Medical training programs, including some in oncology, use this approach to enhance the doctor-patient relationship
Featured Clinical Trial: Sequencing Treatment with a PARP Inhibitor and Chemotherapy
Will giving chemotherapy before olaparib improve the effectiveness of the combination?
UPDATES
NIH Update
- NIH Seeks Ideas for Common Fund
Notes
- Research Funds for Provocative Questions Now Available
- National Cancer Advisory Board Meets Next Week
- President Proclaims September Childhood Cancer Awareness Month
- Research to Reality Cyber-Seminar: Guide to Community Preventive Services
- NCI Conference Focuses on Technologies for Detecting and Diagnosing Cancer in Low- and Middle-Income Countries
Selected articles from past issues of the NCI Cancer Bulletin are available in Spanish.
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.
